Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25
Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Nov 21, 2023, 14:18
5 new drug indications by FDA Oncology in the last 10 days – Oncology Brothers
Quoting Oncology Brothers on X/Twitter:
“What just happened?
5 new drug indications by FDA Oncology in the last 10 days. As Community Oncologists, we need to know them all:
1. Fruquintinib in refractory mCRC, mPFS 3.7mos vs 1.8mos.
2. Pembrolizumab (+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos.
3. Capivasertib (+Fulvestrant) in PIK3CA/AKT1/PTEN +ve metastatic HR+ Breast Ca after >1 endocrine Rx, mPFS 7.2mos Vs 3.6mos.
4. Repotrectinib in 1L mNSCLC ROS1 +ve, ORR 79% and mDoR 34mos.
5. Enzalutamide (+/- ADT) in non-Mets HSPC, 5 year MFS: 87.3% (combo) Vs 80% (Enza monotherapy) Vs 71.4% (ADT alone).”
Source: Oncology Brothers/Twitter